US$16.02-3.1%11月13日 收盘
数据截至2026年9月30日,来自2026年10月28日提交的10-Q
公司指引:2026 财年第 3 季度营收 约 US$209M — 同比增长 11.3%
Just reported
From Neogenomics Inc.'s results release of 2026年10月28日; its quarterly report has since been filed.
Actual
US$209.3M
+11% y/y
+3.8% q/q
Guided
US$209M
midpoint
Actual
-US$7.9M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
| 指标 | 截至该日的 3 个月2026年9月30日 | 截至该日的 3 个月2025年9月30日 | 变动 |
|---|---|---|---|
| 营业收入合计 | US$209.3M | US$187.8M | +11.43% |
| 利润 | -US$7.5M | -US$27.1M | +72.18% |
| 自由现金流 | -US$20.7M | US$570K | -3,724.21% |
这些是单季度数字,不是滚动一年——本站其他地方的数字覆盖十二个月,会大得多。季节性业务在两者之间摆动很大:ServiceNow 在十二月季度赚 20 亿美元自由现金流,在六月季度只有 5 亿。
对比对象是去年同一季度,而不是分析师预测。要说“超预期”或“不及预期”需要一致预期数据,那是我们没有的授权数据——而搞错它比不提更糟。
暂无 Neogenomics Inc. 的业绩电话会文字记录。
“Our third-quarter results reinforce that we have the right strategy in place and the right team to execute against it,”
逐字引自公告,且只在文件将其归于具名人士时才展示。
公告在开盘前或收盘后发布,因此区间从公告日前一个交易日的收盘价到公告日之后那个交易日的收盘价——无论哪种情况,反应都包含在内。
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, providing oncologists, pathologists, hospital systems, academic medical centers, and pharmaceutical firms with innovative diagnostic and predictive testing to deliver timely, actionable insights that guide personalized care decisions. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, England. We routinely post information that may be important to investors on our website at https://www.neogenomics.com. Information on, or accessible through, our website is not incorporated by reference into, and is not a part of, this release or any other report or document that we may file with the Securities and Exchange Commission (“SEC”).
公司自己的描述,取自公告末尾。
引述和公司简介来自 Neogenomics Inc. 于 2026年10月28日 提交的第 2.02 项 8-K 文件;表格根据其季度报告编制。 在 EDGAR 上阅读公告 股价已按拆股和分红复权。